AMGN Stock: Amgen Inc. Stock Price, Analysis & Insights
Get live amgn stock price $320.20, comprehensive Amgen Inc. stock analysis, charts, news, and expert forecast. Real-time amgn stock data and investment insights.
Loading chart...
Company Overview
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Company Information
- CEO
- Robert A. Bradway
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 28000
Contact Information
- Website
- https://www.amgen.com
- Address
- One Amgen Center Drive
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Market leader with 172.4 billion market capitalization
✓ Strong presence in the Healthcare sector with established market position
✓ Growth-oriented company with premium valuation (P/E: 24.7)
✓ Lower volatility stock (Beta: 0.46) may provide portfolio stability
Business Model & Strategy
Amgen Inc. operates in the Drug Manufacturers - General industry, focusing on medical services, pharmaceutical development, and healthcare delivery. As a mid-cap company, Amgen Inc. benefits from scale advantages, market presence, and established operations. Under the leadership of CEO Robert A. Bradway, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Drug Manufacturers - General model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Amgen Inc. competes in the Drug Manufacturers - General within the broader Healthcare. With 172.4 billion in market capitalization, the company is positioned as a established player in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Global Select, Amgen Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Amgen Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Amgen Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for mid-cap stocks
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Amgen Inc.
- ⚠Investors should consider how Amgen Inc. fits within their overall portfolio allocation
Market Cap
172.42B
P/E Ratio
24.74
Beta
0.46
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 172.42B market capitalization
- Trading Volume: 2.66M shares traded today
- Price Range: 52-week range of $253.30 - $335.88
- Exchange: Listed on NASDAQ Global Select
Financial Metrics
Market Analysis for Amgen Inc.
Amgen Inc. (AMGN) operates in the Drug Manufacturers - General industry within the Healthcare sector. With a current market capitalization of 172.42B, the company represents a significant player in its market. The stock is currently trading at $320.20 with a positivedaily change of 1.46%.
The company's 28000 employee base and presence on the NASDAQ Global Selectexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of 24.74, beta of 0.46, and 52-week price range from $253.30 to $335.88when evaluating investment opportunities.
Why Invest in Amgen Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Select)
- • Experienced leadership under Robert A. Bradway
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.